LEQEMBI

This brand name is authorized in United States. It is also authorized in Lithuania.

Active ingredients

The drug LEQEMBI contains one active pharmaceutical ingredient (API):

1	Lecanemab UNII 12PYH0FTU9 - LECANEMAB
	Lecanemab is an IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta and reduces amyloid beta plaques.
	Read more about Lecanemab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LEQEMBI Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
LEQEMBI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06DX04		N Nervous system → N06 Psychoanaleptics → N06D Anti-dementia drugs → N06DX Other anti-dementia drugs
Discover more medicines within N06DX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1103302, 1103303
US	FDA, National Drug Code	62856-212, 62856-215